Jasper Therapeutics has announced that they will be presenting groundbreaking preclinical data on the effectiveness of Briquilimab, an anti-CD117 antibody, in preventing a wide range of allergic reactions in mice. The study specifically targets mice that express chimeric human and mouse CD117, and the results are highly promising.
The presentations will take place at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting on February 23-25, 2024. The details of each presentation are as follows:
1. Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell Depletion.
– Poster Number: 024
– Session Title: Therapeutic Trials in Allergic Skin Disorders and Anaphylaxis 2024
– Session Type: Poster Session
– Session Date / Time: Friday, February 23, 2024; 3:15 p.m. – 4:15 p.m. EST
2. Abstract Title: Briquilimab, an Anti-CD117 Antibody, Prevents Cockroach Allergen Induced Allergic Asthma in Mice Expressing Chimeric Human and Mouse CD117.
– Publication Number: 441
– Session Title: Old Therapeutics and New Targets in Asthma
– Session Type: Oral Abstract Session
– Session Date / Time: Saturday, February 24, 2024; 2:00 p.m. – 3:15 p.m. EST
3. Abstract Title: Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117.
– Poster Number: 747
– Session Title: Around the Horn: Dermatology, Drug Allergy, Anaphylaxis, Insect Hypersensitivity
– Session Type: Featured Poster Session
– Session Date / Time: Sunday, February 25, 2024; 4:45 p.m. – 6:15 p.m. EST
These presentations highlight the potential of Briquilimab in preventing various allergic reactions in mice, specifically targeting chimeric human and mouse CD117. The research conducted by Jasper Therapeutics may have significant implications for the development of therapeutics for allergic conditions in humans. Stay tuned for the groundbreaking findings from this study.
JSPR Stock Analysis: Mixed Performance and Stable Price Range on February 5, 2024
On February 5, 2024, JSPR stock exhibited mixed performance, with a slight drop during regular trading hours followed by a modest increase in after-hours trading. According to data from CNN Money, JSPR was trading in the middle of its 52-week range on that day, indicating that the stock price was relatively stable. JSPR was also trading above its 200-day simple moving average, which is a positive sign for investors. In terms of price change, JSPR shares experienced a decrease of $0.18 since the market last closed, representing a 1.47% drop. Despite the drop during regular trading hours, JSPR stock showed resilience in after-hours trading, rising by $0.47. Overall, investors should consider various factors to gain a more comprehensive understanding of JSPR’s performance and prospects.
JSPR Stock Performance: Analyzing Net Income and EPS Increase for Informed Investment Decisions
On February 5, 2024, investors eagerly awaited the stock performance of JSPR. JSPR reported a net income of -$37.69 million in the past year, representing a decrease of 23.0% compared to the previous year. JSPR’s EPS for the past year was reported at -$10.33, an increase of 61.59% compared to the previous year. However, it is essential to note that while the increase in EPS may seem promising, it should be interpreted with caution, considering the decline in net income. Investors and analysts would likely need more information, such as JSPR’s total revenue, to gain a comprehensive understanding of the company’s financial health and make informed investment decisions.
